Results 91 to 100 of about 2,211,257 (305)

Unusual presentation of primary lung adenocarcinoma mimicking pneumonia: Case report and literature review

open access: yesRespiratory Medicine Case Reports, 2019
Primary lung adenocarcinoma, diffuse pneumonic type, can mimic the clinical presentation of an infectious or inflammatory lung disease, which can represent a diagnostic challenge.
Asil Daoud   +3 more
doaj   +1 more source

Expression of FAT1 in Lung Adenocarcinoma and Its Relationship 
with Immune Cell Infiltration

open access: yesChinese Journal of Lung Cancer
Background and objective Lung cancer is a leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) is the most common pathological subtype, with adenocarcinoma being the predominant type.
Chen DING   +10 more
doaj   +1 more source

Expression of TTF-1 and CK-7 in the Diagnosis of Pleural Effusion Cytology Suspected Lung Adencarcinoma [PDF]

open access: yes, 2015
Background : Lung cancer is the mayor disease that cause death worldwide including Indonesia especially Nonsmall cell lung cancer (NSCLC) consisting of adenocarcinoma, squamus carcinoma (SqCCA) and large cell carcinoma.
Pawitra, I. (Ika)   +2 more
core  

Achalasia secondary to lung adenocarcinoma

open access: yesThe Korean Journal of Internal Medicine, 2015
To the Editor, Pseudoachalasia is a rare entity and is difficult to distinguish from idiopathic achalasia. The most common cause of achalasia secondary to neoplasia is adenocarcinoma of the distal esophagus and the gastroesophageal junction. The second most common cause is small-cell lung cancer [1]. We report a case of lung adenocarcinoma secondary
Burak Can   +5 more
openaire   +3 more sources

Cell death-based treatment of lung adenocarcinoma

open access: yesCell Death and Disease, 2018
The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of all lung cancer cases. In spite of achievements in understanding the pathogenesis of this disease and the development of new approaches in its treatment, unfortunately,
T. Denisenko   +2 more
semanticscholar   +1 more source

Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma

open access: yesMolecular Therapy: Nucleic Acids, 2019
Long non-coding RNAs (lncRNAs) have emerged as key regulators of cellular progress in lung adenocarcinoma. In this study, to identify cancer-related lncRNAs and genes, we screened for those lncRNAs that were differentially expressed in lung ...
Shu-Feng Xu   +10 more
doaj   +1 more source

THORACIC CT-SCAN WITH EGFR MUTATIONS IN PULMONARY ADENOCARCINOMA PATIENTS WITH PULMONARY METASTASES AT DR. MOEWARDI HOSPITAL, SURAKARTA, INDONESIA

open access: yesMajalah Biomorfologi, 2023
Highlights • The thoracic CT scan can be an alternative evaluation before administering EGFR-targeting medicine to patients. • EGFR is now a therapeutic target for lung cancer.
Viska Wahyu Arianti   +5 more
doaj   +1 more source

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. [PDF]

open access: yes, 2019
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance.
A Hübner   +66 more
core   +1 more source

Aspergillus fumigatus enhances elastase production in pseudomonas aeruginosaco-cultures [PDF]

open access: yes, 2015
In the cystic fibrosis (CF) lung the presence of bacteria and fungi in the airways promotes an inflammatory response causing progressive lung damage, ultimately leading to high rates of morbidity and mortality.
Kerr, Stephen   +6 more
core   +1 more source

HLA-G Expression in Lung Adenocarcinoma Tissues and Its Relationship with Prognosis

open access: yesZhongliu Fangzhi Yanjiu, 2018
Objective To investigate the expression of HLA-G and determine the prognostic value of HLA-G for lung adenocarcinoma. Methods The genomic alternation of HLA-G was analyzed using cBioPortal analytic tool.
ZHANG Wenlong   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy